LymphBridge™
LymphBridge™ is a clinical study that is currently enrolling patients with breast cancer-related lymphedema to evaluate the therapeutic benefit of using the BioBridge© Collagen Matrix as an adjunct to Lymph Node Transfer in improving the surgical outcome of the treatment lymphedema.
This multi-site study is being conducted at the University of Chicago Medicine, Stanford Medicine and MD Anderson and has been supported with funding provided by the U.S National Cancer Institute (NCI).
Enroll in the LymphBridge™ study to be part of the solution
The LymphBridge™ clinical study is open to women who are 18 to 75 years of age who are breast cancer survivors that have developed lymphedema, at least 1 year beyond completion of cancer therapy, free of clinical disease and eligible for surgical intervention. Candidates must also meet detailed inclusion and exclusion criteria as defined in the study protocol to be selected for enrolled in the study.
Learn more today
For additional information about the LymphBridge™ study, please visit clinicaltrials.gov.
